Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 3 (2006), Issue 4 (April)

1. Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML).
   Blood, 107(8): 3279-87. [Abstract] [Full-text]
2. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha.
   Blood, 107(8): 3339-41. [Abstract] [Full-text]
3. Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation.
   J Leukoc Biol, 79(4): 747-56. [Abstract] [Full-text]
4. Cardiotoxic effects of arsenic trioxide/imatinib mesilate combination in rats.
   J Pharm Pharmacol, 58(4): 567-73. [Abstract] [Full-text]
5. The Effect of Imatinib Mesylate on the Contractility of Isolated Rabbit Myometrial Strips.
   Gynecol Obstet Invest, 62(2): 79-83. [Abstract] [Full-text]
6. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
   Clin Cancer Res, 12(7): 2239-47. [Abstract] [Full-text]
7. Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants.
   Semin Respir Crit Care Med, 27(2): 158-70. [Abstract] [Full-text]
8. Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib).
   Mol Pharmacol, 69(5): 1527-33. [Abstract] [Full-text]
9. New assignments for multitasking signal transduction inhibitors.
   Mol Pharmacol, 69(5): 1510-2. [Abstract] [Full-text]
10. Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha/gamma ligand TZD18.
    Blood, 107(9): 3683-92. [Abstract] [Full-text]
11. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
    J Cutan Pathol, 33(4): 280-5. [Abstract] [Full-text]
12. Imatinib mesylate inhibits proliferation of rheumatoid synovial fibroblast-like cells and phosphorylation of Gab adapter proteins activated by platelet-derived growth factor.
    Clin Exp Immunol, 144(2): 335-41. [Abstract] [Full-text]
13. Sunitinib malate for the treatment of solid tumours: a review of current clinical data.
    Expert Opin Investig Drugs, 15(5): 553-61. [Abstract] [Full-text]
14. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia.
    Leukemia, 20(5): 827-32. [Abstract] [Full-text]
15. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
    Cancer, 106(9): 2005-11. [Abstract] [Full-text]
16. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
    Clin Cancer Res, 12(8): 2622-7. [Abstract] [Full-text]
17. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
    Proc Natl Acad Sci U S A, 103(17): 6688-93. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.